Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of ...
An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A collection of skills for AI coding agents by Guy on Simulink. Skills in this repository are designed to work with the Simulink Agentic Toolkit. Make sure you install the Simulink Agentic Toolkit ...
See Statistics Help for definitions of terms used.
Abstract: This article presents a third-order noise-shaping (NS) successive approximation register (SAR) analog-to-digital converter (ADC), which exploits a hybrid ...
Permanent Magnet Synchronous Motors (PMSMs) are brushless and have very high reliability and efficiency. Due to their permanent magnet rotor, they also have higher torque with smaller frame size and ...
Abstract: Pipelined ADCs with high speed (≥1 GS/s) and high resolution (≥14b) are required for wireless communication and instrumentation applications. The conventional pipelined architecture is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results